Anteris Technologies Announces Public Offering and Strategic Private Placement Totaling Up to $290M
AVR has more than doubled off its 52-week low of $2.34 on elevated volume (4.6× avg).
Summary
Anteris Technologies Global Corp. is raising up to $290 million through a public offering and a concurrent private placement with a Medtronic plc subsidiary, addressing its 'going concern' warning and funding critical clinical trials.
Key Events · Financing and Capital Events · AVR
-
Significant Capital Raise
Anteris Technologies is conducting a public offering of $200 million in common stock and a concurrent private placement of up to $90 million, totaling up to $290 million.
-
Strategic Investment by Medtronic Subsidiary
Covidien Group S.à r.l., a wholly-owned subsidiary of Medtronic plc, is participating in the private placement at the public offering price, with a maximum purchase of 19.99% of outstanding shares post-offering.
-
Addresses Going Concern
This financing is critical for the company, which previously disclosed 'substantial doubt about its ability to continue as a going concern,' providing essential capital for operations.
-
Funding for Pivotal Trial
Proceeds will primarily fund the ongoing PARADIGM Trial for the DurAVR® Transcatheter Heart Valve System and expand manufacturing capabilities.
Analysis · AVR · Industrial Applications And Services
This substantial capital raise is critical for Anteris Technologies, a development-stage company that explicitly disclosed "substantial doubt about its ability to continue as a going concern." The up to $290 million in new funding, which represents a significant portion of its current market capitalization, will be used to advance its pivotal PARADIGM Trial for the DurAVR® THV System, expand manufacturing, and support general operations. While highly dilutive, this financing provides a necessary lifeline, removing immediate liquidity concerns and enabling the company to progress its key product development. The concurrent private placement with a Medtronic plc subsidiary is a significant strategic development, offering validation for Anteris' technology and potential future collaboration opportunities, including a non-voting board observer right and negotiation rights for future acquisition proposals.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1137 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVR was trading at $6.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $236.9M. The 52-week trading range was $2.34 to $8.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.